| Source publication date | (updated; first published 2026-04-14) |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men |
| Source | Superpower |
| URL | superpower.com/guides/hcg (opens in a new tab) |
Specific Claim Evaluated
hCG acts on the LH receptor of Leydig cells, is FDA approved for hypogonadotropic hypogonadism in men, and co-administration with testosterone can maintain spermatogenesis that would otherwise be suppressed.
Primary Research Supporting or Contradicting the Claim
In a retrospective series of 26 hypogonadal men, low-dose hCG with testosterone maintained semen parameters and no patient became azoospermic (Hsieh et al., 2013).
Corrected Evidence-Based Interpretation
The article is correct. Evidence for hCG with testosterone comes from small retrospective series.
Rationale for Grade
The page states the regulatory status accurately, identifies when cited studies used combination therapy or measured intratesticular testosterone and acknowledges the small size of monotherapy studies.
References
- Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol. 2013;189(2):647-650. PMID
Supporting excerpt: "No patient became azoospermic during concomitant testosterone replacement and human chorionic gonadotropin therapy."